2713 Rituximab Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids 174722-31-7 36105.69499999999 Clear solution (A308). 61°C (FAB fragment), 71°C (whole mAb) >10 mg/mL Intravenous Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. Free toxin may be removed by opsonization via the reticuloendothelial system (primarily the liver and kidneys) or it may be degraded through cellular internalization via the lysosomes. Lysosomes are membrane-enclosed organelles that contain an array of digestive enzymes, including several proteases. Half Life: 0.8 hours (mammalian reticulocytes, in vitro) No indication of carcinogenicity to humans (not listed by IARC). For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Rituxan may cause hepatitis B virus reactivation, stomach, bowel and heart problems, increase the chances for getting infections. Other health effects may include progressive multifocal leukoencephalopathy, infusion reactions, tumor lysis syndrome , and severe skin reactions (RxList A308, A328). Significant esophageal or gastrointestinal tract irritation or burns may occur following ingestion. (L1160) 2009-07-15T20:45:27Z 2014-12-24T20:25:49Z Rituximab P01857 DB00073 1AJ7 true Exogenous Liquid CHEMBL1201576 2osl_bio_r_500.jpg image/jpeg 45158 2014-10-14T18:14:01Z BSEQ0005514